EMEA-000402-PIP02-11-M05
Key facts
| Invented name |
Vimpat
|
| Active substance |
lacosamide
|
| Therapeutic area |
Neurology
|
| Decision number |
P/0001/2018
|
| PIP number |
EMEA-000402-PIP02-11-M05
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of epilepsy with partial-onset seizures
|
| Route(s) of administration |
|
| Contact for public enquiries |
UCB Pharma S.A.
Tel. +44 1753677251 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|
| Compliance procedure number |
EMEA-C-000402-PIP02-11-M05
|
| Compliance opinion date |
27/07/2018
|
| Compliance outcome |
positive
|